drugset / Trial / NCT07247370

Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)

NCT07247370

NaSingle-groupOpen-labelTreatment

Summary

To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.

Timeline

Start
2025-12-10
Primary completion
2027-04-10
Completion
2027-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.7 mg/kg Subcutaneous
Subject Ketamine Small molecule 1.2 mg/kg Subcutaneous